Zhangzhou Pien Tze Huang Pharmaceutical

Corporate brand

Zhangzhou Pien Tze Huang is a Chinese traditional-medicine and health-care brand built around the protected Pien Tze Huang formula and a broader portfolio of pharmaceuticals, health products, and cosmetics. Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. is a Chinese national high-tech pharmaceutical enterprise and China Time-honored Brand whose signature Pien Tze Huang product has a history of nearly 500 years.

Last updated October 9, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Zhangzhou Pien Tze Huang Pharmaceutical is a Chinese pharmaceutical company associated with Pien Tze Huang, a proprietary traditional Chinese medicine preparation originating in Zhangzhou, Fujian. The name Pien Tze Huang is commonly explained as referring to an inflammation-reducing medicinal substance, although the product's formula and manufacturing process are treated as proprietary. The remedy is sold primarily in pill, capsule, and related dosage forms and is marketed for traditional-medicine indications involving inflammation, liver-related discomfort, bruising, and other conditions. Product claims and permitted indications depend on the applicable Chinese regulatory registration and should not be treated as independent medical advice. The commercial history of the brand combines a long-standing traditional formula with a modern corporate structure. The preparation is traditionally linked to a Ming-dynasty-era medicine associated with physicians serving the imperial court and is particularly identified with Zhangzhou. The modern company was established in 1999 and was subsequently listed on the Shanghai Stock Exchange. Its corporate identity is therefore distinct from the much older history attributed to the formula: the company is a modern listed manufacturer, while the brand's cultural and medicinal provenance extends much further back. Pien Tze Huang is the company's flagship product and the core of its brand equity. The company has developed a broader portfolio that includes traditional Chinese medicines, pharmaceutical preparations, healthcare products, cosmetics and skincare products, and related consumer offerings. Its skincare business uses the Pien Tze Huang name and associated traditional-medicine positioning, allowing the company to extend the brand beyond oral medicines into personal care. The group has also maintained activities involving raw-material cultivation, pharmaceutical manufacturing, distribution, and international trade. The brand is strongly associated with scarcity, authenticity, and traditional prestige. Production has been linked to controlled access to several traditional medicinal ingredients, including musk, and the company has taken measures to protect the product from counterfeiting and unauthorized distribution. These characteristics have contributed to premium pricing and to demand from consumers seeking the product as a household remedy, gift, or Chinese traditional-medicine item. They have also exposed the brand to supply, conservation, regulatory, and price-sensitivity issues. The company serves the domestic Chinese market through pharmacies, hospitals or medical channels where applicable, distributors, retail outlets, e-commerce, and company-operated or authorized channels. It has also sold products in Hong Kong and overseas markets, especially in parts of Southeast Asia with established Chinese-medicine communities. The brand remains active and is best understood as a public Chinese traditional-pharmaceutical company rather than merely as a single over-the-counter product brand. Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. is a national high-tech enterprise, national technological innovation demonstration enterprise, China Time-honored Brand and national civilized unit whose main business is pharmaceutical manufacturing and R&D; its market value ranks first in the traditional Chinese medicine segment of listed companies. The company exclusively produces Pien Tze Huang, a product with a history of nearly 500 years, described as a national first-class protected traditional Chinese medicine variety and a famous Chinese TCM product. Its product range includes Pien Tze Huang, Pien Tze Huang (OTC version), Pien Tze Huang capsules, Angong Niuhuang Wan and other medicines, health foods and export products. The company's shares are listed on the Shanghai Stock Exchange under the name "片仔癀" with code 600436. Zhangzhou Pien Tze Huang is the principal brand of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., a Chinese pharmaceutical company headquartered in Zhangzhou, Fujian. The company is best known for Pien Tze Huang, a traditional Chinese medicinal preparation whose claimed lineage reaches back to the late Ming period. The product is associated with traditional indications including heat-clearing, blood-circulation support, swelling reduction, and pain relief, although consumers should rely on approved labeling and professional medical advice rather than brand descriptions alone. The modern corporate enterprise grew from Zhangzhou Pharmaceutical Factory, established in 1956. In December 1999, the former Pien Tze Huang Group and other institutional shareholders reorganized the operating assets into the joint-stock company now known as Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. The company completed a public offering and became listed on the Shanghai Stock Exchange in 2003 under ticker 600436. It remains controlled by Zhangzhou Jiulongjiang Group, a municipal state-owned enterprise, with ultimate control attributed to the Zhangzhou State-owned Assets Supervision and Administration Commission. Pien Tze Huang occupies an unusual position in the Chinese medicine market because its prescription and manufacturing process are treated as state-protected confidential information. It has also been recognized as a national first-class protected traditional Chinese medicine variety, while its traditional manufacturing craft has been included in China’s intangible cultural heritage system. The product is manufactured in limited formats, principally a traditional ingot form and a capsule form. The company states that both forms share the same principal ingredients and approved therapeutic functions. The use of musk and other controlled or scarce medicinal materials has made supply security, regulatory policy, sourcing, and production capacity important commercial considerations. The company’s business is broader than the flagship medicine. Its pharmaceutical portfolio includes Angong Niuhuang Pill, Yindan Pinggan Capsules, Compound Pien Tze Huang Lozenges, Chuanbei Qingfei Syrup, Compound Pien Tze Huang Ointment, Compound Pien Tze Huang Hemorrhoid Ointment, Jintangning Capsules, and Xinshubao Tablets. These products address areas such as liver-related medicines, respiratory and throat complaints, dermatology, diabetes-related care, cardiovascular health, and other traditional Chinese medicine categories. The company also operates pharmaceutical distribution businesses and has developed a cosmetics and personal-care portfolio using the Pien Tze Huang, Queen, and Golden Doctor brands. Its positioning combines heritage, scarcity, regulated pharmaceutical status, and modern research. The company presents Pien Tze Huang as a Chinese medicine symbol connected with overseas trade and the maritime Silk Road, while its current strategy seeks to extend the brand into health, beauty, research, distribution, and investment. The cosmetics business emphasizes Chinese ingredients, skin health, brightening care, and an “Oriental” or new Chinese beauty identity; the Queen line is positioned around classic skin care and mature-skin care. The brand has a strong presence in Chinese pharmacies and has historically maintained significant export activity. Industry materials cited in the supplied references describe Pien Tze Huang and related products as particularly competitive in retail-pharmacy liver-medicine categories. The company’s commercial strength is also linked to its ability to set prices for the flagship product, which has been subject to repeated announced price adjustments since the company’s listing. That pricing power supports premium positioning but also exposes the brand to affordability concerns, supply shortages, speculation, raw-material constraints, and public scrutiny. In the mid-2020s, Zhangzhou Pien Tze Huang continued to pur…

History

The history of Zhangzhou Pien Tze Huang Pharmaceutical has two layers: the traditional history of the Pien Tze Huang remedy and the more recent history of the listed company that manufactures and commercializes it. The formula is traditionally associated with Zhangzhou in Fujian Province and is commonly traced in company and secondary accounts to the Ming dynasty. One version of the origin story connects it with physicians serving the imperial court who later brought the preparation to southern China. The historical narrative has helped make Pien Tze Huang an emblematic Zhangzhou product, although the details of the early story are part of the brand's traditional heritage rather than a fully documented modern corporate chronology. The remedy became known as Pien Tze Huang and was transmitted through local pharmaceutical practice. Its distinctive identity rests on a proprietary formula, a controlled manufacturing process, and a reputation for difficult-to-obtain ingredients. Musk has been identified in descriptions of the traditional formulation, and the availability and regulation of such ingredients have been important to the company's sourcing and product-management responsibilities. The formula's proprietary character and the brand's long local association allowed Pien Tze Huang to develop a position unlike that of a generic traditional-medicine product. A modern corporate enterprise was established in 1999 as Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. The company brought the heritage product into a standardized industrial and commercial setting, with formal pharmaceutical production, quality control, distribution, and corporate governance. It later became a Shanghai-listed company under ticker 600436. The listing gave the business access to public capital markets and made it one of the more visible Chinese traditional-medicine companies, while the Pien Tze Huang product remained the principal source of brand recognition. Over time, the company expanded beyond the original dosage form. Its portfolio has included Pien Tze Huang pills and capsules, related traditional Chinese medicines, healthcare preparations, cosmetics, and skincare products. The skincare range extends the heritage positioning into consumer personal care, using traditional-medicine associations and the Pien Tze Huang name to support a premium image. This diversification reduces dependence on a single product category but also requires the company to manage different regulatory classifications, channels, consumer expectations, and competitive environments. The company has built distribution in mainland China and has developed international sales, including markets in Hong Kong and Southeast Asia. Overseas demand is supported by the familiarity of Chinese traditional medicine among Chinese diaspora communities and by the product's reputation as a distinctive regional medicine. At the same time, international expansion requires compliance with local rules governing medicines, supplements, cosmetics, advertising, importation, and medical claims. Pien Tze Huang's commercial strength has been closely connected with perceived authenticity and limited availability. Counterfeit products and unauthorized sales have been recurring risks for valuable traditional brands, encouraging the company to use packaging controls, channel management, and anti-counterfeiting measures. Scarce or regulated ingredients create another long-term challenge: the company must balance continuity of supply with conservation obligations, regulatory requirements, and the need to preserve the product's traditional identity. In the present, Zhangzhou Pien Tze Huang Pharmaceutical remains an active public Chinese pharmaceutical company. It is best characterized as a heritage traditional-medicine enterprise with a flagship proprietary remedy and adjacent businesses in pharmaceuticals, healthcare, cosmetics, and skincare. Its continuing development depends on maintaining trust in the authenticity and quality of Pien Tze Huang, broadening its product portfolio responsibly, adapting to changing Chinese healthcare and consumer regulations, and translating a regional traditional-medicine identity into sustainable domestic and international operations. According to the company's brand story, in the late Ming dynasty a court physician brought the Pien Tze Huang secret formula to Zhangzhou and became a monk at Pushan Yan Temple; using the palace formula with precious Chinese medicinal materials such as musk, cow bezoar, notoginseng and snake gall, he prepared medicinal ingots for treating heat-toxin swelling and pain, and the formula was passed down within the temple. In the late Qing and early Republic period, as the temple declined, the last abbot returned to lay life and continued making and selling Pien Tze Huang at the Xinyuan Tea House outside the east gate of Zhangzhou, bringing it from the Buddhist temple into the folk sphere, where it was regarded as a "treasure to guard the home" and flowed with overseas Chinese into Southeast Asia. After the founding of New China, in 1956 the government carried out socialist transformation of private industry and commerce, and Xinyuan Tea House joined with pharmacies including Tongshantang to form the joint public-private Tongshantang United Pharmaceutical Factory; in December 1957, Tongshantang United Pharmaceutical Factory merged with the joint public-private Cunheng United Shenqu Factory and was renamed the joint public-private Zhangzhou Pharmaceutical Factory, with Pien Tze Huang as its leading product. In 1993, Zhangzhou Pien Tze Huang Group Company was established with Zhangzhou Pharmaceutical Factory as the core enterprise. In December 1999, with Zhangzhou Pien Tze Huang Group Company as the main promoter together with other legal entities, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was established. In June 2003, the company's shares were listed on the Shanghai Stock Exchange under the stock abbreviation "片仔癀" with code 600436, becoming a pillar enterprise of Zhangzhou. The company states that Pien Tze Huang's formula and process are listed as a state secret and have never been leaked, and are listed as a national first-class protected traditional Chinese medicine variety, the highest level of protection for Chinese patent medicines; the "片仔癀" registered trademark became a state-approved special case combining drug name, trademark name and stock name. In 2005, five ministries including the State Forestry Administration, State Food and Drug Administration and State Administration for Industry and Commerce jointly issued an announcement providing that except for a very few Chinese patent medicines such as Pien Tze Huang, other Chinese patent medicines not listed may not continue to use natural musk; from July 1, 2005, each Pien Tze Huang pill bears an individually numbered "China Wildlife Management Special Mark" and is produced in limited quantities. In 2017, the Pien Tze Huang "Fujian Three Treasures" gift box was selected as a candidate national gift for the BRICS leaders' meeting in Xiamen and won the national gift selection team award. The commercial history of Zhangzhou Pien Tze Huang has two layers: the long traditional history claimed for the medicine itself and the much shorter history of the modern corporate group. Company materials trace Pien Tze Huang to the late Ming period, describing nearly five centuries of transmission. The formula and manufacturing process are treated as confidential state-protected information, so public descriptions do not disclose a complete recipe or production method. This secrecy, together with the product’s protected status and traditional manufacturing craft, forms the core of the brand’s identity. The modern industrial base began with Zhangzhou Pharmaceutical Factory in 1956. The factory became the source of the pharmaceutical operations later consolidated under the Pien Tze Huang group. In December 1999, the former Zhangzhou Pien Tze Huang Group acted as the principal sponsor in establishing Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., alongside other institutional shareholders. The restructuring placed the relevant pharmaceutical operating assets into a joint-stock company and created the corporate platform that later developed the Pien Tze Huang brand beyond a single medicinal product. The company went public in 2003 on the Shanghai Stock Exchange. Its public offering documentation identified Pien Tze Huang as the dominant product and highlighted several structural risks: dependence on the flagship medicine, the importance of overseas sales, and the regulatory control of musk supplies. These issues continued to shape the company’s strategy. The flagship medicine provided strong brand recognition and premium pricing, but concentration also meant that production volume, raw-material availability, regulatory changes, and consumer demand could have an outsized effect on the business. Over time, the company expanded its portfolio of traditional Chinese medicines. Alongside Pien Tze Huang in ingot and capsule formats, it developed or marketed Angong Niuhuang Pill, Yindan Pinggan Capsules, Compound Pien Tze Huang Lozenges, Chuanbei Qingfei Syrup, topical ointments, and other products. The portfolio reached liver-care, respiratory, dermatological, cardiovascular, diabetes-related, pediatric, and gynecological categories. The company also built pharmaceutical distribution subsidiaries, allowing it to participate in commercial circulation as well as manufacturing. A significant strategic shift occurred during the 2010s, when management articulated a broader health-care development approach often summarized as a core pharmaceutical business with two supporting areas. The core remained traditional Chinese medicine and other pharmaceuticals. The supporting areas included cosmetics, daily chemical products, health foods, and other health-related products. This approach led to greater emphasis on the Pien Tze Huang cosmetics brand and related labels such as Queen and Golden Doctor. The cosmetics business used the company’s heritage and Chinese botanical-ingredient associations to pursue a modern Chinese beauty position, including skin brightening and mature-skin care. The company’s public profile grew through pharmacy distribution, exports, heritage branding, and research. Pien Tze Huang has been described in supplied industry materials as a leading product in Chinese retail-pharmacy liver-medicine categories. The traditional production craft was included in China’s intangible cultural heritage framework, and the flagship medicine was recognized as a national first-class protected traditional Chinese medicine variety. Both Pien Tze Huang and Angong Niuhuang Pill were reported as authorized to use natural musk under applicable approvals, reinforcing their differentiation while also making procurement and conservation-related regulation strategically important. Governance became a prominent issue in the early 2020s. Liu Jianshun, who had served as chairman from 2014, applied for early retirement in 2021, after which Pan Jie briefly became chairman and later gave way to Lin Weiqi. The rapid succession of chairmen attracted attention. In August 2023, Zhangzhou disciplinary authorities announced that Liu had been expelled from the Communist Party and that alleged disciplinary and legal violations, including suspected bribery, had been transferred for prosecution. This was a matter concerning a former executive rather than a finding that the brand’s products were defective, but it remains an important part of the company’s governance history. In the mid-2020s, the group continued to pursue research, investment, and supply-chain expansion. Reported activities included participation in health-care investment funds, exploration of pharmaceutical intellectual property, and a proposed acquisition involving Zhangzhou Mingyuan Flavors and its interest in Shuixian Pharmaceutical. These moves reflected an effort to build a broader health-care ecosystem, although the strategic benefits of some investments remained subject to execution and synergy risks. The company remained publicly listed, state-controlled, and centered on the Pien Tze Huang franchise while seeking growth in medicines, distribution, cosmetics, and adjacent health businesses.

2025
Research and health-care investment remained central priorities
[6]Long-term issuer credit rating reportstockmc.xueqiu.com
The company continued pharmacological research, investment-fund participation, and development of its pharmaceutical and broader health-care ecosystem.
2024
Expansion into adjacent traditional-product assets considered
[10]Report on proposed Mingyuan Flavors acquisitionchnfund.com
The group proposed acquiring Zhangzhou Mingyuan Flavors, whose principal strategic asset was a minority interest in Shuixian Pharmaceutical.
2023
Former chairman disciplined and referred for prosecution
[9]Securities Times report on former chairman Liu Jianshunstcn.com
Authorities announced disciplinary expulsion and referral of former chairman Liu Jianshun in connection with alleged serious violations and suspected bribery.
2021
Chairmanship changed during a period of leadership turnover
[9]Securities Times report on former chairman Liu Jianshunstcn.com
Liu Jianshun retired early, and Pan Jie became chairman before a further change in leadership.
2017
The 'Fujian Three Treasures' gift box featuring Pien Tze Huang was selected as a candidate national gift for the BRICS Xiamen Summit and won the team award for national gift selection works.
2016
On December 25, the Traditional Chinese Medicine Law of the People's Republic of China was adopted, providing special protection for traditional Chinese medicine prescriptions and production processes recognized as state secrets, benefiting Pien Tze Huang.
2014
Broader health-care strategy introduced
[9]Securities Times report on former chairman Liu Jianshunstcn.com
Management promoted a strategy centered on pharmaceuticals with supporting businesses in cosmetics, daily chemical products, health foods, and other health-related areas.
2005
Five ministries including the State Forestry Administration and the State Food and Drug Administration jointly issued a notice allowing only a few Chinese patent medicines such as Pien Tze Huang to continue using natural musk; from July 1, each Pien Tze Huang pill was affixed with a separately numbered 'China Wildlife Management Special Mark' and production was limited.
2003
Shanghai Stock Exchange listing
[1]Pien Tze Huangen.wikipedia.org
The company completed its public offering and listed in Shanghai under ticker 600436.SH.
2003
In June, the company's shares were listed on the Shanghai Stock Exchange under the stock abbreviation 'Pien Tze Huang' with the code 600436, becoming a pillar enterprise of Zhangzhou City.
1999
Modern company established
[1]Pien Tze Huangen.wikipedia.org
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was established as the modern corporate vehicle for manufacturing and commercializing the heritage medicine.
1999
In December, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was established, with Zhangzhou Pien Tze Huang Group Company as the main initiator together with other legal entities.
1999
Modern joint-stock company founded
[7]Initial public offering prospectus summaryvip.stock.finance.sina.com.cn
The former Pien Tze Huang Group and other institutional shareholders established Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. in December.
1993
Zhangzhou Pien Tze Huang Group Company was established with Zhangzhou Pharmaceutical Factory as the core enterprise.
1957
In December, Tongshantang United Pharmaceutical Factory merged with the public-private joint Cunheng United Shenqu Factory and was renamed the public-private joint Zhangzhou Pharmaceutical Factory, with Pien Tze Huang as its leading product.
1956
During the socialist transformation of private industry and commerce, Xinyuan Tea House and Tongshantang and other pharmacies were merged to form the public-private joint Tongshantang United Pharmaceutical Factory.
1956
Zhangzhou Pharmaceutical Factory established
[6]Long-term issuer credit rating reportstockmc.xueqiu.com
The predecessor industrial pharmaceutical operation was established in Zhangzhou and later became the manufacturing foundation of the modern company.
Traditional origin associated with Zhangzhou
[1]Pien Tze Huangen.wikipedia.org
The Pien Tze Huang remedy is traditionally associated with Zhangzhou and is commonly linked in historical accounts to a Ming-dynasty-era formula.
Expansion into skincare and consumer healthcare
[1]Pien Tze Huangen.wikipedia.org
The group extended the Pien Tze Huang identity into skincare, cosmetics, healthcare products, and related traditional-medicine offerings.

Products and positioning

A premium, heritage-based Chinese traditional-medicine brand combining a protected proprietary formula with modern pharmaceutical manufacturing and an expanding healthcare and skincare portfolio. China Time-honored Brand and national intangible cultural heritage; national first-class protected TCM variety; market value ranked first in the TCM segment of listed companies. A premium, heritage-led Chinese medicine and health-care house centered on a state-protected traditional formula, with extensions into pharmaceuticals, distribution, cosmetics, and broader health products.

Traditional Chinese medicine
Pien Tze Huang capsules
The flagship proprietary traditional Chinese medicine associated with the company and with Zhangzhou. It is sold in regulated dosage forms and has traditionally been marketed for inflammation-related and liver-related indications, among other permitted uses. Its formula, manufacturing process, and ingredient sourcing are central to the brand's premium positioning. Actual indications, dosage, and availability depend on the product registration and market in which it is sold. A capsule-format presentation associated with the Pien Tze Huang medicine. The capsule format supports standardized packaging and distribution while extending the core product beyond its traditional pill presentation. It is part of the company's broader effort to provide the flagship medicine in multiple pharmaceutical formats. Clears heat and detoxifies, cools blood and resolves stasis, reduces swelling and relieves pain; used for acute and chronic viral hepatitis, carbuncles and boils, unnamed swellings and toxins, traumatic injuries and various inflammations caused by heat-toxin and blood stasis. National first-class protected TCM variety and famous Chinese TCM product; clears heat and detoxifies, cools blood and resolves stasis, reduces swelling and relieves pain. The flagship traditional Chinese medicine and the foundation of the brand. It is sold principally in a traditional ingot form and is associated in approved labeling with heat-clearing, blood-cooling, blood-circulation support, swelling reduction, and pain relief for specified conditions. Its formula and manufacturing process are protected as confidential information, and the product is recognized as a national first-class protected traditional Chinese medicine variety. A capsule dosage form of the flagship medicine. Company and industry materials describe it as having the same principal ingredients and approved functions as the ingot form, while offering a different administration and packaging format. It is marketed for the same broad approved therapeutic categories as Pien Tze Huang.
Skincare and cosmetics
Pien Tze Huang skincare
A line of personal-care products using the Pien Tze Huang heritage and traditional-medicine associations in a skincare context. The range broadens the brand's consumer reach beyond pharmaceutical products and is positioned around traditional ingredients, heritage, and premium Chinese personal care.
Pien Tze Huang (OTC version)
Clears heat and detoxifies, cools blood and resolves stasis, reduces swelling and relieves pain; used for carbuncles and boils, traumatic injuries caused by heat-toxin and blood stasis.
Traditional Chinese medicine
Angong Niuhuang Wan
Clears heat and detoxifies, calms fright and opens orifices; used for heat disease with pathogen entering the pericardium, high fever and convulsions, delirium, stroke coma and encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, septicemia with the above syndromes. A major traditional Chinese medicine product positioned for heat-clearing and consciousness-opening indications under approved labeling. The company highlights its authorization to use natural musk and its differentiated materials profile. It is one of the group’s most important products outside the core Pien Tze Huang franchise.
Throat medicine
Compound Pien Tze Huang Ganbao
Protects and regulates the liver; for functional impairment caused by excessive smoking and drinking. Clears heat and detoxifies, soothes the throat and relieves pain, promotes fluid and moistens the throat; used for acute and chronic pharyngitis caused by wind-heat attacking upward and excessive heat in the lung and stomach. A lozenge product extending the Pien Tze Huang name into throat and oral-care applications. It represents the company’s strategy of using brand equity and traditional-medicine expertise across additional everyday health categories. A topical preparation associated with the Pien Tze Huang pharmaceutical family. It gives the brand a dermatological application and has been identified in industry materials as one of the company’s stronger non-flagship retail-pharmacy products.
Compound Pien Tze Huang hemorrhoid ointment
Clears heat and detoxifies, dissipates stasis and relieves pain, stops bleeding and treats hemorrhoids; used for internal, external and mixed hemorrhoids.
Zengru Gao
Enriches blood and invigorates blood, dredges collaterals and promotes lactation; used for postpartum insufficient lactation.
Jintangning capsules
Transforms turbidity and dispels dampness, invigorates blood and relieves pain; used for type 2 diabetes with damp-turbidity obstruction and blood stasis syndrome.
Shaolin Zhenggu Jing
Invigorates blood and dispels stasis, reduces swelling and relieves pain, dispels wind and disperses cold; used for traumatic injuries, accumulated stasis and swelling pain, limb numbness and wind-damp.
Liver-care medicine
Yindan Pinggan Capsules
A traditional Chinese medicine capsule product included in the company’s liver-related portfolio. It supports the group’s effort to broaden its liver-care franchise beyond the flagship Pien Tze Huang product and is sold through pharmaceutical and retail channels.
Respiratory medicine
Chuanbei Qingfei Syrup
A traditional Chinese medicine syrup in the company’s respiratory and cough-related portfolio. Its liquid format and familiar herbal positioning complement the group’s solid-dose products and broaden its participation in seasonal and respiratory-care markets.
Cosmetics and personal care
Pien Tze Huang Cosmetics
A cosmetics portfolio built around Chinese ingredients, the company’s heritage, and a new Chinese beauty positioning. The range covers skin care and personal-care products and emphasizes skin health, brightening care, and the translation of traditional brand symbolism into contemporary beauty products.
Cosmetics and personal care
Queen
A related skin-care label positioned as a contemporary classic. Its stated focus is mature-skin care and the modernization of an established Eastern beauty tradition, giving the group a second identity beyond the medicinal flagship.

Controversies

2023
Former chairman Liu Jianshun expelled from the Communist Party and referred to procuratorate
In August 2023, the Zhangzhou Municipal Commission for Discipline Inspection and Supervisory Commission announced that Liu Jianshun, former chairman of Pien Tze Huang Pharmaceutical, was expelled from the Communist Party and stripped of his benefits, and that suspected crimes including bribery were referred to the procuratorate for review and prosecution. This source concerns the disciplinary action and referral stage. Zhangzhou disciplinary authorities stated that former chairman Liu Jianshun had committed serious disciplinary and legal violations, including alleged improper receipt of valuables and money, abuse of position, unlawful business activity, and suspected bribery. He was expelled from the Communist Party, stripped of relevant benefits, and referred for prosecution. The supplied report does not establish product wrongdoing by the brand.
Source 1 Source 2
Drug-Induced Pneumonia Case
Lack of Clinical Trials

2024New Chinese beauty and skin-health positioning
China
The cosmetics business emphasized Chinese ingredients, skin health, brightening care, and an Oriental or new Chinese beauty identity, while the Queen line focused on classic care for mature skin.
Outcome. The campaign architecture gave the group’s beauty activities distinct positioning while retaining a connection to Pien Tze Huang heritage.
Source
2020Heritage-led Chinese medicine and health branding
China · International export markets
The brand promoted its protected formula, traditional craft, long historical lineage, and connection with Chinese cultural heritage in product and corporate communications.
Outcome. The approach reinforced premium positioning and presented Pien Tze Huang as a recognizable Chinese medicine symbol in domestic and overseas markets.
Source
2014One Core, Two Wings health-care strategy
China
The company framed pharmaceuticals and traditional Chinese medicine as its core while developing cosmetics, daily chemical products, health foods, and other health businesses as supporting growth areas.
Outcome. The strategy broadened the corporate brand beyond its flagship medicine and supported later development of cosmetics, investment, distribution, and health-care activities.
Source

Brand decisions

2025
Expansion through research, funds, and health-care ecosystem investmentsStrategy
Background
The group aimed to strengthen its pharmaceutical pipeline and use investment vehicles to connect with medical and health-care opportunities.
Action taken
It continued pharmacological research, participated in investment funds, and pursued pharmaceutical intellectual-property opportunities.
Aftermath
The approach increased the group’s exposure to adjacent health-care sectors while adding capital-allocation and execution risks.
Source
2024
Proposed acquisition of Mingyuan FlavorsM&A
Background
The company identified traditional consumer health products and upstream or adjacent assets as possible extensions of its health-care ecosystem.
Action taken
A wholly owned investment subsidiary proposed acquiring all equity in Zhangzhou Mingyuan Flavors, which held a minority interest in Shuixian Pharmaceutical.
Aftermath
The transaction was presented as a related-party investment intended to create industrial synergies, while external commentary noted that the commercial benefits required further validation.
Proposed transaction consideration. (2024)
Source
2014
Adoption of a diversified health-care strategyStrategy
Background
The company faced concentration risk from its flagship medicine and sought additional growth platforms.
Action taken
Management developed a strategy combining a core pharmaceutical business with supporting cosmetics, daily chemical, health-food, and health-product activities.
Aftermath
The group expanded into cosmetics, distribution, research, and investment while retaining Pien Tze Huang as its central asset.
Source
2003
Public offering and Shanghai listingStrategy
Background
The company sought public capital while relying heavily on the Pien Tze Huang franchise and overseas sales.
Action taken
It completed an initial public offering and listed on the Shanghai Stock Exchange under 600436.SH.
Aftermath
The listing created a public-company platform for pharmaceutical manufacturing, distribution, cosmetics, and later health-care investment.
Source
1999
Creation of a modern pharmaceutical company around the heritage remedyStrategy
Background
The traditional Pien Tze Huang medicine was converted into the core commercial asset of a modern corporate pharmaceutical enterprise.
Action taken
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was established to manufacture, distribute, and develop the product under standardized corporate and pharmaceutical systems.
Aftermath
The move created the corporate platform that later supported public listing, portfolio expansion, and wider domestic and international distribution.
Source
Portfolio expansion beyond the flagship medicineStrategy
Background
Reliance on a single proprietary traditional medicine creates concentration and supply constraints, while the Pien Tze Huang name offers an established platform for adjacent healthcare categories.
Action taken
The company expanded into related traditional medicines, healthcare products, cosmetics, and skincare.
Aftermath
The group developed a broader healthcare and consumer portfolio while retaining Pien Tze Huang as its central brand asset.
Source

Recent events

2025
Investment in the traditional medicine and health-care ecosystem expanded[11]Pien Tze Huang merger and acquisition recordsstock.qianzhan.com
M&A
Company disclosures and industry reporting described participation in health-care investment funds, research projects, and a proposed acquisition of intellectual property related to a traditional-medicine respiratory product.
2025
Long-term issuer rating reported at AAA with a stable outlook[6]Long-term issuer credit rating reportstockmc.xueqiu.com
Other
A published credit-rating report assessed the company’s long-term issuer credit profile at AAA with a stable outlook and highlighted its brand strength, product position, and protected flagship medicines.
2025
The company continued research and development in Pien Tze Huang pharmacology[6]Long-term issuer credit rating reportstockmc.xueqiu.com
Other
The company reported continuing research into the material basis and molecular mechanisms of Pien Tze Huang, as well as exploratory studies involving liver, cardiovascular, and neurological applications.
2024
Proposed acquisition of a stake in Zhangzhou Shuixian Pharmaceutical through Mingyuan Flavors[10]Report on proposed Mingyuan Flavors acquisitionchnfund.com
M&A
A wholly owned investment subsidiary proposed acquiring all equity in Zhangzhou Mingyuan Flavors, whose principal strategic asset was described as a 30% interest in Shuixian Pharmaceutical, a producer associated with traditional topical products such as wind-oil essence.
Pien Tze Huang becomes the focus of renewed consumer and investor attention[1]Pien Tze Huangen.wikipedia.org
Pricing · Other
The company's flagship product has periodically attracted attention because of its premium retail price, constrained ingredient supply, and strong brand demand. No single dated event is identified here because the available reference material does not establish a specific news episode with sufficient certainty.

Sources15 sources

Cite this profile: Cite the canonical profile. /brand-wiki/漳州片仔癀药业 · Editorial policy · How profiles are compiled